Cryofocus Biotechnology Co., Ltd (HKG: 6922), a Shanghai-based specialist in cryoablation treatment, has announced that it has received marketing approvals from China’s National Medical Products Administration (NMPA) for all components of its cardiac cryoablation system. The approvals include the cryoablation equipment, balloon type cryoablation catheter (previously known as the atrial fibrillation cryoablation catheter), and disposable intracardiac mapping catheter (formerly known as the intracardiac mapping catheter), which were approved on December 4th. Additionally, the adjustable curved guide catheter (previously known as the adjustable curved sheath) received approval on December 7th.
The in-house developed cardiac cryoablation system, comprising the aforementioned parts, is hailed as the first cardiac liquid nitrogen frozen balloon ablation product in the market. It is intended for the treatment of drug-resistant, recurrent, and symptomatic paroxysmal atrial fibrillation.- Flcube.com
